9/1/2009

The FDA granted Delcath Systems' doxorubicin orphan-drug designation as a treatment for primary liver cancer. The company said it plans to further test doxorubicin with its Percutaneous Hepatic Perfusion drug-delivery technology.

Full Story:
Reuters, Forbes

Related Summaries